Daiichi Sankyo Company, Limited

MorphoSys and Daiichi Sankyo Forge Alliance to Develop Novel Antibody Therapies against Hospital-Acquired Infections [Press Release]
MarketWire | 35 days 22 hours 26 minutes ago
MARTINSRIED, GERMANY and MUNICH, GERMANY -- (Marketwire) -- 10/20/09 --

LILLY (ELI) & COMPANY - Effient Recommendations in PCI-STEMI Guidelines [Press Release]
PRNewswire | 6 days 8 hours 24 minutes ago
Date: November 18, 2009 Refer to: Tammy Hull Eli Lilly and Company 317-651-9116 (office) 317-614-5132 (cell) Kimberly Wix Daiichi Sankyo (U.S.A.) 973-944-2338 (office) 908-656-5447 (cell) Shigemichi Kondo Daiichi Sankyo (Tokyo) 81-3-6225-1126 (office)

LILLY (ELI) & COMPANY - Research Update [Press Release]
PRNewswire | 8 days 13 hours 31 minutes ago
Date: Nov. 15, 2009 Refer to: Derin Denham Eli Lilly and Company +1-317-277-6749 (office) +1-317-370-1435 (cell) Dr. Michaela Paudler-Debus Daiichi Sankyo Europe GmbH +49-(0)89-78 08 685 (office) +49-(0)172-845 8974 (cell) Shigemichi Kondo Daiichi Sankyo (Tokyo) 81-3-6225-1126 (office)

New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI [Press Release]
PRNewswire | 6 days 8 hours 46 minutes ago
...medical director for Daiichi Sankyo, Inc. "Based on the...forming around stents." Daiichi Sankyo Company, Limited , and Eli Lilly and Company co-developed Effient...antiplatelet agent discovered by Daiichi Sankyo and its Japanese research...

Effient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease [Press Release]
PRNewswire | 9 days 6 hours 57 minutes ago
...ACS.(3) Daiichi Sankyo Company, Limited , and Eli Lilly and Company co-developed...discovered by Daiichi Sankyo and its Japanese...Eli Lilly and Company, +1-317...Kimberly Wix, Daiichi Sankyo (U.S.A...

Research and Markets: Antibiotics - Global Trends Report: Geographic Coverage and Vertical Market Analysis [Press Release]
Business Wire | 6 days 17 hours 56 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/ff5934/antibiotics_glob) has announced the addition of the "Antibiotics - Global Trends" report to their offering.

Ranbaxy Launches Authorized Generic Version of Rocaltrol(R) [Press Release]
PRNewswire | 83 days 21 hours 55 minutes ago
...Ranbaxy Laboratories Limited (RLL), India...largest pharmaceutical company. RPI is engaged...Ranbaxy Laboratories Limited, headquartered...international pharmaceutical company producing a wide...a subsidiary of Daiichi Sankyo Company, Ltd...

Effient(TM) is Now Available in Pharmacies [Press Release]
PRNewswire | 111 days 19 hours 55 minutes ago
...Exchange. Daiichi Sankyo and Lilly undertake...DSLLOGO Eli Lilly and Company CONTACT: Tammy Hull, Eli Lilly and Company, +1-317-651...Kimberly Wix, Daiichi Sankyo Inc. (U.S.A...Kondo, DaiichiSankyo Limited (Tokyo), 81...

Ranbaxy Receives Final Approval to Manufacture and Market Glycopyrrolate Tablets [Press Release]
PRNewswire | 92 days 17 hours 56 minutes ago
...Ranbaxy Laboratories Limited (RLL), India...largest pharmaceutical company. RPI is engaged...Ranbaxy Laboratories Limited, headquartered...international pharmaceutical company producing a wide...a subsidiary of Daiichi Sankyo Company, Ltd...

Ranbaxy Receives Final Approval To Market Sumatriptan Succinate Tablets [Press Release]
PRNewswire | 105 days 19 hours 26 minutes ago
...Ranbaxy Laboratories Limited (RLL), India...largest pharmaceutical company. RPI is engaged...Ranbaxy Laboratories Limited, headquartered...international pharmaceutical company producing a wide...a subsidiary of Daiichi Sankyo Company, Ltd...

Welchol(R) (colesevelam HCl) Receives FDA Approval to Lower LDL Cholesterol in Pediatric Patients with Heterozygous Familial Hypercholesterolemia [Press Release]
PRNewswire | 48 days 20 hours 53 minutes ago
PARSIPPANY, N.J., Oct. 7 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol(R) (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin afte...

Reportlinker Adds Prescription Drugs Report [Press Release]
PRNewswire | 77 days 18 hours 25 minutes ago
...Ranbaxy Laboratories Limited, Sanofi-Aventis SA...Takeda Pharmaceutical Company Limited, Teva Pharmaceutical...secondary research. Company profiles are mostly...II-93 Forest and Daiichi Sankyo Sign Contract to Co...